SCHEMBL7705103

SCHEMBL7705103

CC(C)(C)c1cc(OCC2CO2)ccc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 1/20 0.49
ALDH1A1 P00352 4/20 0.48
TP53 P04637 3/20 0.48
TSHR P16473 3/20 0.48
HIF1A Q16665 2/20 0.48
CYP3A4 P08684 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
CYP1A2 P05177 1/20 0.47
PPARG P37231 1/20 0.47
GLA P06280 1/20 0.43
FGFR1 P11362 1/20 0.42
SRC P12931 1/20 0.42
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
MAOB P27338 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1354705 0.87 ALDH1A1 (0.56) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL29721135 0.84 TDP1 (0.57) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL21657603 0.84 TDP1 (0.57) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL8730031 0.84 TDP1 (0.57) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL8730039 0.84 TDP1 (0.57) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL30628474 0.84 TDP1 (0.57) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL8758127 0.81 TDP1 (0.53) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL8758115 0.81 TDP1 (0.53) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL7469751 0.81 TDP1 (0.53) MEN1KMT2ATDP1ALDH1A1TP53
SCHEMBL6139629 0.81 TDP1 (0.47) MEN1KMT2ATDP1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6358515-B2 ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION; TREATMENT OF GLAUCOMA SENJU PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US disclosed
US-20010008893-A1 HYDROQUINONE DERIVATIVES SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-07-19 US disclosed
EP-0972766-A1 HYDROQUINONE DERIVATIVES Senju Pharmaceutical Co., Ltd. (JP) 2000-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010008893-A1 HYDROQUINONE DERIVATIVES REN, AGTR1, AGTR2 MEN1 2775/4885KMT2A 2128/4885TDP1 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.